Enteric fever, comprising typhoid and paratyphoid fever, remains a significant global health concern. Although the incidence has declined in developed nations, it continues to pose challenges in developing countries. This article provides an updated approach to the diagnosis and management of enteric fever.
The gold standard for diagnosing enteric fever is blood culture, which has a sensitivity of 40-60%. Bone marrow culture increases sensitivity to 80%, but its invasive nature limits its use. Widal test, though widely used, has poor sensitivity and specificity. Recent advances include PCR-based tests and the Typhidot test, which are promising but require further validation.
Antibiotic therapy remains the mainstay of treatment. The choice of antibiotics has evolved due to increasing antimicrobial resistance. Fluoroquinolones, once first-line, are now reserved for severe cases due to widespread resistance. Current first-line agents include ceftriaxone and azithromycin. Vaccination is crucial for prevention, with two vaccines currently available: Vi polysaccharide vaccine and Ty21a vaccine.
A growing concern in enteric fever management is antimicrobial resistance, particularly multi-drug resistant (MDR) and extensively drug-resistant (XDR) strains. MDR strains are resistant to traditional first-line drugs (chloramphenicol, ampicillin, and trimethoprim-sulfamethoxazole), while XDR strains are resistant to fluoroquinolones and third-generation cephalosporins. These trends necessitate ongoing surveillance and stewardship efforts.
In conclusion, the approach to diagnosing and managing enteric fever has evolved with advances in diagnostic methods and shifts in antimicrobial resistance patterns. Clinicians must stay abreast of these changes to provide effective patient care. Future research should focus on improving diagnostic accuracy and developing new therapeutic strategies to combat resistant strains.
1.
Regular physical activity before cancer diagnosis may lower progression and death risks
2.
Medication Self-Injection Embraced by Breast Cancer Patients
3.
Financial hardship for cancer survivors due to high-cost immunotherapies, especially for blood cancer patients
4.
FDA Advisors Split on Regimens for Breast, Prostate Cancers
5.
ctDNA-Guided Adjuvant Therapy Cuts Bladder Cancer Costs
1.
RDW-CV vs. MCV: Knowing the Difference Can Help You Better Understand Your Health
2.
Clinical Pathways in Hematology in Clinical Decision-Making
3.
Immune Surveillance Screening for Early Cancer Risk Detection
4.
Unlocking the Mysteries of Lymphoblastic Lymphoma: A Journey Into the Unknown
5.
AI-Driven Digital Pathology in Oncology: From Histology Images to Predictive Treatment Biomarkers
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
How Advances in Cancer Research Are Improving Treatment Options
2.
Navigating the Complexities of Ph Negative ALL - Part II
3.
Signs and Symptoms of Leukemia
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Virtual Case Study on Elephantiasis of Lower Limb- An Initiative by Hidoc Dr.
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation